SuperworthViking Therapeutics shares outstanding VKTX
Diluted shares outstanding, averaged over each quarter, from 2014.
- Latest quarter, to Jun 30, 2026
- 116.3M
- On a year earlier
- +3.7%
- more shares
Viking Therapeutics had 116.3M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 3.7% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 114M | +2% |
| FY2024 | 111.3M | +11% |
| FY2023 | 99.9M | +30% |
| FY2022 | 76.6M | −2% |
| FY2021 | 78.1M | +7% |
| FY2020 | 72.9M | +1% |
| FY2019 | 72.1M | +1% |
| FY2018 | 71.3M | +139% |
| FY2017 | 29.9M | +50% |
| FY2016 | 19.9M | +296% |
| FY2015 | 5M | +5% |
| FY2014 | 4.8M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 116.3M | +4% | |
| Q1 FY26 | 115.6M | +3% | |
| Q4 FY25 | 114M | +2% | |
| Q3 FY25 | 112.3M | +1% | |
| Q2 FY25 | 112.1M | +2% | |
| Q1 FY25 | 112.1M | +8% | |
| Q4 FY24 | 111.3M | +11% | |
| Q3 FY24 | 110.9M | +11% | |
| Q2 FY24 | 110.4M | +11% | |
| Q1 FY24 | 103.5M | +32% | |
| Q4 FY23 | 99.9M | +30% | |
| Q3 FY23 | 99.8M | +31% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Viking Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.